Buy Tenofovir Emtricitabine

Tenofovir Emtricitabine

What is Tenofovir Emtricitabine?

Tenofovir Emtricitabine is a fixed-dose combination tablet that contains the active ingredients Tenofovir Disoproxil and Emtricitabine. It belongs to the class of antiretroviral medicines used to treat Human Immunodeficiency Virus (HIV) infection. In the United Kingdom the product is prescription-only (POM) and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The tablet is marketed in a single strength of 300 mg Tenofovir Disoproxil / 200 mg Emtricitabine, taken orally.

How Tenofovir Emtricitabine Works in the Body

Tenofovir Disoproxil and Emtricitabine are both nucleos(t)ide reverse transcriptase inhibitors (NRTIs). After oral absorption, Tenofovir Disoproxil is converted to tenofovir, and Emtricitabine is phosphorylated inside cells. Both active metabolites mimic natural nucleotides and become incorporated into the viral DNA chain during reverse transcription. This incorporation:

• Terminates DNA elongation because the analogues lack a 3′-hydroxyl group.
• Prevents the HIV reverse transcriptase enzyme from completing the synthesis of proviral DNA.

The result is reduced viral replication, a decline in plasma HIV-1 RNA (viral load), and preservation of immune function. Onset of antiviral activity occurs within hours of the first dose, with steady-state concentrations achieved after about 7 days of once-daily dosing. The drugs are eliminated primarily by the kidneys; tenofovir is excreted unchanged, while emtricitabine undergoes renal tubular secretion.

Conditions Treated with Tenofovir Emtricitabine

In the UK, Tenofovir Emtricitabine is approved for the treatment of HIV-1 infection in adults as part of a complete antiretroviral regimen. It is indicated for:

• Initial therapy in combination with other antiretroviral agents (e.g., integrase inhibitors, protease inhibitors).
• Switch therapy for patients already virologically suppressed who require regimen simplification or a change due to toxicity.

The medication is not approved as a standalone therapy; it must be prescribed alongside at least two additional active agents to achieve durable viral suppression.

Off-Label and Investigational Applications

Evidence from clinical studies supports the use of Tenofovir-based regimens for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in high-risk individuals. While Tenofovir Emtricitabine (as a single tablet) is commonly used for PrEP, this indication is not formally approved by the MHRA and requires careful medical supervision.

Disclaimer: Off-label use of Tenofovir Emtricitabine requires individualized risk assessment and ongoing monitoring by a qualified healthcare professional.

Who Should (Not) Use Tenofovir Emtricitabine?

Ideal Candidates

• Adults with confirmed HIV-1 infection who need a backbone NRTI component in their regimen.
• Individuals with normal renal function (estimated creatinine clearance ≥ 60 mL/min).

Absolute Contraindications

• Known hypersensitivity to Tenofovir Disoproxil, Emtricitabine, or any excipients in the tablet.
• Severe renal impairment (creatinine clearance < 30 mL/min) - the drug is contraindicated because accumulation can lead to toxicity.

Relative Contraindications & Special Populations

• Pregnancy: Tenofovir and Emtricitabine are classified as Category B3 (UK). They are generally considered safe, but benefits must outweigh potential risks.
• Breastfeeding: Limited data; use only if clearly needed.
• Elderly: Monitor renal function closely; dose adjustment may be required.
• Co-infection with hepatitis B: Tenofovir also suppresses hepatitis B virus; abrupt discontinuation can cause hepatitis flare.

If uncertainty exists about suitability, patients should discuss their full medical history with a prescriber.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal discomfort (nausea, mild diarrhea) - usually transient.
• Headache - often mild and resolves with continued therapy.
• Fatigue - may improve as viral load declines.

Serious Adverse Events

• Renal toxicity - manifested as increased serum creatinine or decreased eGFR; requires prompt evaluation.
• Bone mineral density loss - long-term use can contribute to osteopenia/osteoporosis, especially in patients with pre-existing risk factors.
• Lactic acidosis (rare) - presents with hyperventilation, abdominal pain, and elevated lactate; constitutes a medical emergency.

Drug Interactions

• Didanosine - co-administration is contraindicated due to enhanced risk of pancreatitis and peripheral neuropathy.
• Non-steroidal anti-inflammatory drugs (NSAIDs) - may increase the risk of renal impairment; monitor kidney function.
• Antacids containing aluminum or magnesium - can reduce absorption of Tenofovir; separate dosing by at least 2 hours.
• Other nephrotoxic agents (e.g., aminoglycosides, vancomycin) - may compound renal toxicity; dose adjustments or alternative therapy recommended.

Food and Lifestyle Interactions

• The tablet may be taken with or without food; a consistent routine improves adherence.
• Moderate alcohol consumption does not directly interact, but excess intake can worsen hepatic health and adherence.
• No specific restrictions on driving; however, patients experiencing dizziness or severe fatigue should avoid operating machinery.

How to Take Tenofovir Emtricitabine

• Standard dosing: One tablet containing 300 mg Tenofovir Disoproxil and 200 mg Emtricitabine taken once daily, preferably at the same time each day.
• Renal adjustment: For patients with creatinine clearance 30-49 mL/min, the recommended dose is one tablet every 48 hours; for clearance < 30 mL/min the medication is contraindicated.
• Administration: Swallow the tablet whole with a glass of water; do not crush or chew.
• Missed dose: Take the missed dose as soon as remembered unless it is close to the next scheduled dose; do not double-dose.
• Overdose: Symptoms may include nausea, vomiting, abdominal pain, and decreased urination. Seek emergency medical attention; supportive care and gastric lavage are typical measures.
• Discontinuation: Abrupt cessation can lead to viral rebound. Switching to another antiretroviral regimen should be performed under medical supervision, often with a brief overlap to maintain viral suppression.

Monitoring and Follow-Up

• Renal function: Serum creatinine and eGFR should be checked at baseline, then at 1 month, and every 3-6 months thereafter.
• HIV viral load: Measured 4-8 weeks after initiation and periodically to confirm suppression (< 50 copies/mL).
• Hepatitis B status: If co-infected, monitor hepatitis B DNA levels and liver enzymes.
• Bone health: Assess risk factors for osteoporosis; consider baseline DEXA scan in patients with other risk markers.

Regular clinical review ensures efficacy, detects early toxicity, and supports adherence.

Storage and Handling

• Keep the tablets in the original blister pack until use.
• Store at room temperature (15-25 °C), protected from moisture and direct sunlight.
• Do not use after the expiry date printed on the package.
• Keep out of reach of children; dispose of unused tablets according to local pharmacy take-back programs.

Medication-Specific Glossary

Reverse Transcriptase Inhibitor

A class of drugs that block the HIV enzyme reverse transcriptase, preventing conversion of viral RNA into DNA.

Viral Load

The quantity of HIV RNA copies per milliliter of blood; a primary marker of treatment effectiveness.

Therapeutic Window

The dosage range in which a drug achieves the desired effect without causing unacceptable toxicity.

Resistance

The ability of HIV to replicate despite the presence of antiretroviral drugs, often due to genetic mutations.

Nucleos(t)ide Analogue

A synthetic compound resembling natural nucleotides, incorporated into viral DNA to terminate chain elongation.

Medical Disclaimer

This article provides educational information about Tenofovir Emtricitabine and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.